Search

Your search keyword '"Nevola, Riccardo"' showing total 262 results
Start Over Author "Nevola, Riccardo"
262 results on '"Nevola, Riccardo"'

1. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis

Author

Iannone, Giulia, Serri, Paola, Bertino, Gaetano, Balsano, Clara, Iapadre, Nerio, Maida, Marcello, Sacerdoti, David, Natola, Leonardo Antonio, Ciacci, Carolina, Santonicola, Antonella, Cozzolongo, Raffaele, Surace, Lorenzo Antonio, Fracanzani, Anna Ludovica, Cespiati, Annalisa, Federico, Alessandro, Romeo, Mario, Grieco, Antonio, Marrone, Giuseppe, Vizioli, Luca, Di Cola, Simone, D’Amico, Gennaro, Caraceni, Paolo, Schepis, Filippo, Loredana, Simone, Lampertico, Pietro, Toniutto, Pierluigi, Martini, Silvia, Maimone, Sergio, Colecchia, Antonio, Svegliati Barone, Gianluca, Alessandria, Carlo, Aghemo, Alessio, Crocè, Saveria Lory, Adinolfi, Luigi Elio, Rendina, Maria, Lapenna, Lucia, Pompili, Enrico, Zaccherini, Giacomo, Saltini, Dario, Iavarone, Massimo, Tosetti, Giulia, Martelletti, Carolina, Nassisi, Veronica, Ferrarese, Alberto, Giovo, Ilaria, Masetti, Chiara, Pugliese, Nicola, Campigotto, Michele, Nevola, Riccardo, and Merli, Manuela

Published
2024
Full Text
View/download PDF

2. Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study

Author

Nevola, Riccardo, Feola, Giovanni, Ruocco, Rachele, Russo, Antonio, Villani, Angela, Fusco, Raffaele, De Pascalis, Stefania, Core, Micol Del, Cirigliano, Giovanna, Pisaturo, Mariantonietta, Loffredo, Giuseppe, Rinaldi, Luca, Marrone, Aldo, Starace, Mario, Sposito, Pellegrino De Lucia, Cozzolino, Domenico, Salvatore, Teresa, Lettieri, Miriam, Marfella, Raffaele, Sasso, Ferdinando Carlo, Coppola, Nicola, and Adinolfi, Luigi Elio

Published
2023
Full Text
View/download PDF

4. The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial

Author

Sasso, Ferdinando Carlo, Simeon, Vittorio, Galiero, Raffaele, Caturano, Alfredo, De Nicola, Luca, Chiodini, Paolo, Rinaldi, Luca, Salvatore, Teresa, Lettieri, Miriam, Nevola, Riccardo, Sardu, Celestino, Docimo, Giovanni, Loffredo, Giuseppe, Marfella, Raffaele, Adinolfi, Luigi Elio, and Minutolo, Roberto

Published
2022
Full Text
View/download PDF

6. Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment?

Author

Nevola, Riccardo, Russo, Antonio, Scuotto, Samuel, Imbriani, Simona, Aprea, Concetta, Abitabile, Marianna, Beccia, Domenico, Brin, Chiara, Carusone, Caterina, Cinone, Francesca, Cirigliano, Giovanna, Colantuoni, Sara, Cozzolino, Domenico, Cuomo, Giovanna, Del Core, Micol, Gjeloshi, Klodian, Marrone, Aldo, Medicamento, Giulia, Meo, Luciana Agnese, Nappo, Francesco, Padula, Andrea, Pafundi, Pia Clara, Ranieri, Roberta, Ricozzi, Carmen, Rinaldi, Luca, Romano, Ciro Pasquale, Ruocco, Rachele, Ruosi, Carolina, Salvati, Annabella, Sasso, Ferdinando Carlo, Sellitto, Ausilia, Sommese, Pino, Villani, Angela, Coppola, Nicola, and Adinolfi, Luigi Elio

Published
2022
Full Text
View/download PDF

7. Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration.

Author

Rosato, Valerio, Nevola, Riccardo, Dallio, Marcello, Di Micco, Pierpaolo, Spinetti, Angiola, Zeneli, Laert, Ciancio, Alessia, Milella, Michele, Colombatto, Piero, D'Adamo, Giuseppe, Rosselli Del Turco, Elena, Gallo, Paolo, Falcomatà, Andrea, De Nicola, Stella, Pugliese, Nicola, D'Ambrosio, Roberta, Soria, Alessandro, Colella, Elisa, Federico, Alessandro, and Brunetto, Maurizia

Subjects
*ANTICOAGULANTS, *ORAL medication, *HEPATITIS C virus, *ANTIVIRAL agents, *CYTOCHROME P-450
Abstract

Background: Direct oral anticoagulants (DOACs) are recommended for the management of thrombosis prophylaxis, especially in patients with atrial fibrillation. As substrates of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein, they are implicated in potential drug–drug interactions. NS5A/NS5B inhibitors are direct-acting agents (DAAs) against the Hepatitis C Virus (HCV) infection that exert a mild inhibition of P-glycoprotein without effects on CYP3A4. A DOAC and NS5A/NS5B inhibitor co-administration may lead to an increased risk of bleeding. Real-world data on the concomitant use of DOACs and DAAs are scarce. On this purpose, we perform a retrospective analysis on the risk of vascular adverse events (bleeding and thrombosis) among HCV patients under DOAC/DAA therapy, even in advanced liver disease. Methods: Between May 2015 and April 2023, patients treated with sofosbuvir-based DAA regimens and DOACs were consecutively included in this study from 12 Italian medical centers. Baseline characteristics, especially concerning bleeding risk and liver function, were collected. The occurrence of bleeding events, classified as major and minor, was the primary endpoint. Secondary endpoints were the rate of any thrombotic events and/or the need for discontinuation of one or both treatments. Moreover, a cohort of patients, matched by demographic characteristics (age and sex), that switched to vitamin K antagonists (VKAs) during the antiviral treatment was compared with the DOAC/DAA group. Results: A total of 104 patients were included. Thirty-eight of them (36.5%) were cirrhotic. Atrial fibrillation was an indication for anticoagulation in almost all cases (76%). Rivaroxaban (35.6%) was the most used DOAC, followed by apixaban (26.9%), dabigatran (19.2%) and edoxaban (18.3%). Sofosbuvir/velpatasvir (78.8%) was the most prescribed DAA, and all patients were already on anticoagulant therapy before the start of DAAs. During concomitant DOAC/DAA treatment, no major bleeding events were recorded, while four minor bleeding events occurred, but none resulted in DAA or DOAC discontinuation. At univariate analysis, the only additional risk factor statistically related to bleeding events was the anticoagulant therapy (hazard ratio [HR]: 13.2, 95% confidence interval 1,6-109). Performing an evaluation by a LOGIT binomial analysis with demographic characteristics, the antiplatelet therapy remained statistically associated to bleeding events. No significant differences were found in the rate of clinically relevant bleeding when the main population was compared with the VKA-switched cohort. A single major bleeding event leading to anticoagulation and DAA discontinuation was reported in VKA-switched matched cohort. Conclusions: In our study, the concomitant use of NS5A/NS5B inhibitors with DOAC showed good safety, and the only risk factor associated with bleeding events was the concomitant antiplatelet therapy. These findings support the use of DOACs during sofosbuvir-based HCV treatment, even in advanced liver disease. Replacing DOACs with VKAs does not appear to be of clinical benefit. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis

Author

Di Cola, Simone, primary, D’Amico, Gennaro, additional, Caraceni, Paolo, additional, Schepis, Filippo, additional, Loredana, Simone, additional, Lampertico, Pietro, additional, Toniutto, Pierluigi, additional, Martini, Silvia, additional, Maimone, Sergio, additional, Colecchia, Antonio, additional, Svegliati Barone, Gianluca, additional, Alessandria, Carlo, additional, Aghemo, Alessio, additional, Crocè, Saveria Lory, additional, Adinolfi, Luigi Elio, additional, Rendina, Maria, additional, Lapenna, Lucia, additional, Pompili, Enrico, additional, Zaccherini, Giacomo, additional, Saltini, Dario, additional, Iavarone, Massimo, additional, Tosetti, Giulia, additional, Martelletti, Carolina, additional, Nassisi, Veronica, additional, Ferrarese, Alberto, additional, Giovo, Ilaria, additional, Masetti, Chiara, additional, Pugliese, Nicola, additional, Campigotto, Michele, additional, Nevola, Riccardo, additional, Merli, Manuela, additional, Iannone, Giulia, additional, Serri, Paola, additional, Bertino, Gaetano, additional, Balsano, Clara, additional, Iapadre, Nerio, additional, Maida, Marcello, additional, Sacerdoti, David, additional, Natola, Leonardo Antonio, additional, Ciacci, Carolina, additional, Santonicola, Antonella, additional, Cozzolongo, Raffaele, additional, Surace, Lorenzo Antonio, additional, Fracanzani, Anna Ludovica, additional, Cespiati, Annalisa, additional, Federico, Alessandro, additional, Romeo, Mario, additional, Grieco, Antonio, additional, Marrone, Giuseppe, additional, and Vizioli, Luca, additional

Published
2024
Full Text
View/download PDF

10. Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA Study

Author

Caturano, Alfredo, primary, Galiero, Raffaele, additional, Vetrano, Erica, additional, Medicamento, Giulia, additional, Alfano, Maria, additional, Beccia, Domenico, additional, Brin, Chiara, additional, Colantuoni, Sara, additional, Di Salvo, Jessica, additional, Epifani, Raffaella, additional, Nevola, Riccardo, additional, Marfella, Raffaele, additional, Sardu, Celestino, additional, Coppola, Carmine, additional, Scarano, Ferdinando, additional, Maggi, Paolo, additional, Calabrese, Cecilia, additional, De Lucia Sposito, Pellegrino, additional, Rescigno, Carolina, additional, Sbreglia, Costanza, additional, Fraganza, Fiorentino, additional, Parrella, Roberto, additional, Romano, Annamaria, additional, Calabria, Giosuele, additional, Polverino, Benedetto, additional, Pagano, Antonio, additional, Numis, Fabio Giuliano, additional, Bologna, Carolina, additional, Nunziata, Mariagrazia, additional, Esposito, Vincenzo, additional, Coppola, Nicola, additional, Maturo, Nicola, additional, Nasti, Rodolfo, additional, Di Micco, Pierpaolo, additional, Perrella, Alessandro, additional, Adinolfi, Luigi Elio, additional, Di Domenico, Marina, additional, Monda, Marcellino, additional, Russo, Vincenzo, additional, Ruggiero, Roberto, additional, Docimo, Giovanni, additional, Rinaldi, Luca, additional, and Sasso, Ferdinando Carlo, additional

Published
2024
Full Text
View/download PDF

12. Validation of the BAP-65 score for prediction of in-hospital death or use of mechanical ventilation in patients presenting to the emergency department with an acute exacerbation of COPD: a retrospective multi-center study from the Italian Society of Emergency Medicine (SIMEU)

Author

Adinolfi, Luigi Elio, Alvisi, Antonella, Antonio, Pagano, Azin, Giulia, Balloni, Andrea, Bandiera, Geminiano, Barchetti, Marco, Barillari, Alfredo, Barozzi, Marco, Belloni, Giulia, Belotti, Eugenia, Binetti, Nicola, Bonora, Miriam, Bruni, Rosamaria, Cacco, Silvia, Camisa, Daniele, Carbone, Giorgio, Carpinteri, Giuseppe, Catino, Laura, Cazzaniga, Massimo, Cenni, Patrizia, Chelli, Vittorio, Cicero, Leonora, Cottone, Carlo Domenico, Cuccia, Filippa, D'Angelo, Luciano, Dalmonte, Francesca, Daviddi, Fabio, De Vita, Anna, Famà, Fausto, Fedele, Marta, Fonti, Caterina, Frigerio, Marta, Gallingani, Alan, Ghiglione, Valeria, Gioffrè-Florio, Maria, Giordano, Mauro, Giostra, Fabrizio, Galli, Maria Giulia, Greggi, Maria Elena, Groff, Paolo, Guizzardi, Stefano, Lagasio, Chiara, Lazzara, Giuseppe, Lubini, Eloisa, Magni, Laura, Mancarella, Sandro, Mangano, Giuseppe, Maragno, Margherita, Menabue, Monia, Meoni, Eleonora, Molinaro, Federica, Morelli, Alice, Moscariello, Francesco, Nevola, Riccardo, Noto, Paola, Paladino, Fiorella, Pancani, Roberta, Petrelli, Giuseppina, Petrino, Roberta, Sinno, Carmine, Tafa, Aferdita, Tartaglia, Sergio, Taurino, Chiara, Treleani, Martina, Villari, Liliana, Vitelli, Alessandra, Zaccagni, Cinzia, Zaccaro, Bruna, Zacchino, Massimo, Germini, Federico, Veronese, Giacomo, Marcucci, Maura, Coen, Daniele, Ardemagni, Deborah, Montano, Nicola, and Fabbri, Andrea

Published
2019
Full Text
View/download PDF

13. Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination

Author

Nevola, Riccardo, Criscuolo, Livio, Beccia, Domenico, Delle Femine, Augusto, Ruocco, Rachele, Imbriani, Simona, Alfano, Maria, Villani, Angela, Russo, Antonio, Perillo, Pasquale, Marfella, Raffaele, Adinolfi, Luigi Elio, Sasso, Ferdinando Carlo, Marrone, Aldo, Rinaldi, Luca, Nevola, Riccardo, Criscuolo, Livio, Beccia, Domenico, Delle Femine, Augusto, Ruocco, Rachele, Imbriani, Simona, Alfano, Maria, Villani, Angela, Russo, Antonio, Perillo, Pasquale, Marfella, Raffaele, Adinolfi, Luigi Elio, Sasso, Ferdinando Carlo, Marrone, Aldo, and Rinaldi, Luca

Subjects
Cirrhosi, SARS-CoV-2 infection, Chronic liver disease, Gastroenterology, COVID-19, General Medicine, Liver injury, Non-alcoholic fatty liver disease
Abstract

Since the first identification in December of 2019 and the fast spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, it has represented a dramatic global public health concern. Though affecting mainly the respiratory system, SARS-CoV-2 disease, defined as coronavirus disease 2019 (COVID-19), may have a systemic involvement leading to multiple organ dysfunction. Experimental evidence about the SARS-CoV-2 tropism for the liver and the increasing of hepatic cytolysis enzymes during infection support the presence of a pathophysiological relationship between liver and SARS-CoV-2. On the other side, patients with chronic liver disease have been demonstrated to have a poor prognosis with COVID-19. In particular, patients with liver cirrhosis appear extremely vulnerable to infection. Moreover, the etiology of liver disease and the vaccination status could affect the COVID-19 outcomes. This review analyzes the impact of the disease stage and the related causes on morbidity and mortality, clinical outcomes during SARS-CoV-2 infection, as well as the efficacy of vaccination in patients with chronic liver disease.

Published
2023

14. Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy.

Author

Galiero, Raffaele, Loffredo, Giuseppe, Simeon, Vittorio, Caturano, Alfredo, Vetrano, Erica, Medicamento, Giulia, Alfano, Maria, Beccia, Domenico, Brin, Chiara, Colantuoni, Sara, Di Salvo, Jessica, Epifani, Raffaella, Nevola, Riccardo, Marfella, Raffaele, Sardu, Celestino, Coppola, Carmine, Scarano, Ferdinando, Maggi, Paolo, Calabrese, Cecilia, and De Lucia Sposito, Pellegrino

Subjects
HEPATIC fibrosis, HOSPITAL mortality, HOSPITAL admission & discharge, COVID-19, COVID-19 pandemic
Abstract

Background & aims: SARS-Cov-2 infection manifests as a wide spectrum of clinical presentation and even now, despite the global spread of the vaccine, contagiousness is still elevated. The aim of the study was the evaluation of the impact of liver fibrosis assessed by FIB-4 and liver impairment, assessed by cytolysis indices, on intrahospital mortality in COVID-19 subjects. Methods: This is a retrospective observational cohort study, which involved 23 COVID Hospital Units in Campania Region, Italy. Exposure variables were collected during hospital admission and at discharge. According to FIB-4 values, we subdivided the overall population in three groups (FIB-4<1.45; 1.453.25), respectively group 1,2,3. Results: At the end of the study, 938 individuals had complete discharged/dead data. At admission, 428 patients were in group 1 (45.6%), 387 in group 2 (41.3%) and 123 in group 3 (13.1%). Among them, 758 (81%) subjects were discharged, while the remaining 180 (19%) individuals died. Multivariable Cox's regression model showed a significant association between mortality risk and severity of FIB-4 stages (group 3 vs group 1, HR 2.12, 95%CI 1.38–3.28, p<0.001). Moreover, Kaplan-Meier analysis described a progressive and statistically significant difference (p<0.001 Log-rank test) in mortality according to FIB-4 groups. Among discharged subjects, 507 showed a FIB-4<1.45 (66.9%, group 1), 182 a value 1.453.25 (9.0%, group 3). Among dead subjects, 42 showed a FIB-4<1.45 (23.3%, group 1), 62 a value 1.453.25 (42.3%, group 3). Conclusions: FIB-4 value is significantly associated with intrahospital mortality of COVID-19 patients. During hospitalization, particularly in patients with worse outcomes, COVID-19 seems to increase the risk of acute progression of liver damage. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Liver Involvement during SARS-CoV-2 Infection Is Associated with a Worse Respiratory Outcome in COVID-19 Patients

Author

Romano, Ciro, primary, Cozzolino, Domenico, additional, Nevola, Riccardo, additional, Abitabile, Marianna, additional, Carusone, Caterina, additional, Cinone, Francesca, additional, Cuomo, Giovanna, additional, Nappo, Francesco, additional, Sellitto, Ausilia, additional, Umano, Giuseppina Rosaria, additional, Adinolfi, Luigi Elio, additional, Marrone, Aldo, additional, and Rinaldi, Luca, additional

Published
2023
Full Text
View/download PDF

16. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

Author

Petta, Salvatore, Adinolfi, Luigi Elio, Fracanzani, Anna Ludovica, Rini, Francesca, Caldarella, Rosalia, Calvaruso, Vincenza, Cammà, Calogero, Ciaccio, Marcello, Di Marco, Vito, Grimaudo, Stefania, Licata, Anna, Marrone, Aldo, Nevola, Riccardo, Pipitone, Rosaria Maria, Pinto, Antonio, Rinaldi, Luca, Torres, Daniele, Tuttolomondo, Antonino, Valenti, Luca, Fargion, Silvia, and Craxì, Antonio

Published
2018
Full Text
View/download PDF

17. COPD exacerbations in the emergency department: Epidemiology and related costs. A retrospective cohort multicentre study from the Italian Society of Emergency Medicine (SIMEU)

Author

Adinolfi, Luigi Elio, Alvisi, Antonella, Azin, Giulia, Balloni, Andrea, Bandiera, Geminiano, Barchetti, Marco, Barillari, Alfredo, Barozzi, Marco, Belloni, Giulia, Belotti, Eugenia, Binetti, Nicola, Bonora, Miriam, Bruni, Rosamaria, Cacco, Silvia, Camisa, Daniele, Carbone, Giorgio, Carpinteri, Giuseppe, Catino, Laura, Cazzaniga, Massimo, Cenni, Patrizia, Chelli, Vittorio, Cicero, Leonora, Cottone, Carlo Domenico, Cuccia, Filippa, D'Angelo, Luciano, Dalmonte, Francesca, Daviddi, Fabio, De Vita, Anna, Famà, Fausto, Fedele, Marta, Fonti, Caterina, Frigerio, Marta, Gallingani, Alan, Ghiglione, Valeria, Gioffrè-Florio, Maria, Giordano, Mauro, Giostra, Fabrizio, Galli, Maria Giulia, Greggi, Maria Elena, Groff, Paolo, Guizzardi, Stefano, Lagasio, Chiara, Lazzara, Giuseppe, Lubini, Eloisa, Magni, Laura, Mancarella, Sandro, Mangano, Giuseppe, Maragno, Margherita, Menabue, Monia, Meoni, Eleonora, Molinaro, Federica, Morelli, Alice, Moscariello, Francesco, Nevola, Riccardo, Noto, Paola, Pagano, Antonio, Paladino, Fiorella, Pancani, Roberta, Petrelli, Giuseppina, Petrino, Roberta, Sinno, Carmine, Tafa, Aferdita, Tartaglia, Sergio, Taurino, Chiara, Treleani, Martina, Villari, Liliana, Vitelli, Alessandra, Zaccagni, Cinzia, Zaccaro, Bruna, Zacchino, Massimo, Germini, Federico, Veronese, Giacomo, Marcucci, Maura, Coen, Daniele, Ardemagni, Deborah, Montano, Nicola, and Fabbri, Andrea

Published
2018
Full Text
View/download PDF

20. Long-Term Prognosis among COVID-19 Patients: The Predictive Role Played by Hyperinflammation and Arrhythmic Disorders in Fatal Outcome

Author

Cozzolino, Domenico, primary, Romano, Ciro, additional, Sardu, Celestino, additional, Nevola, Riccardo, additional, Umano, Giuseppina Rosaria, additional, Rinaldi, Luca, additional, Adinolfi, Luigi Elio, additional, Catalini, Christian, additional, Marrone, Aldo, additional, Municinò, Maurizio, additional, Sasso, Ferdinando Carlo, additional, and Marfella, Raffaele, additional

Published
2023
Full Text
View/download PDF

21. Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma

Author

Nevola, Riccardo, primary, Tortorella, Giovanni, additional, Rosato, Valerio, additional, Rinaldi, Luca, additional, Imbriani, Simona, additional, Perillo, Pasquale, additional, Mastrocinque, Davide, additional, La Montagna, Marco, additional, Russo, Antonio, additional, Di Lorenzo, Giovanni, additional, Alfano, Maria, additional, Rocco, Maria, additional, Ricozzi, Carmen, additional, Gjeloshi, Klodian, additional, Sasso, Ferdinando Carlo, additional, Marfella, Raffaele, additional, Marrone, Aldo, additional, Kondili, Loreta Anesti, additional, Esposito, Nicolino, additional, Claar, Ernesto, additional, and Cozzolino, Domenico, additional

Published
2023
Full Text
View/download PDF

23. Mortality and risk factors of vaccinated and unvaccinated COVID-19 frail patients treated with anti-SARS-CoV-2 monoclonal antibodies. A real-world study

Author

Nevola, Riccardo, Feola, Giovanni, Ruocco, Rachele, Russo, Antonio, Villani, Angela, Fusco, Raffaele, De Pascalis, Stefania, Core, Micol Del, Cirigliano, Giovanna, Pisaturo, Mariantonietta, Loffredo, Giuseppe, Rinaldi, Luca, Marrone, Aldo, Starace, Mario, Sposito, Pellegrino De Lucia, Cozzolino, Domenico, Salvatore, Teresa, Lettieri, Miriam, Marfella, Raffaele, Sasso, Ferdinando Carlo, Coppola, Nicola, Adinolfi, Luigi Elio, Nevola, Riccardo, Feola, Giovanni, Ruocco, Rachele, Russo, Antonio, Villani, Angela, Fusco, Raffaele, De Pascalis, Stefania, Core, Micol Del, Cirigliano, Giovanna, Pisaturo, Mariantonietta, Loffredo, Giuseppe, Rinaldi, Luca, Marrone, Aldo, Starace, Mario, Sposito, Pellegrino De Lucia, Cozzolino, Domenico, Salvatore, Teresa, Lettieri, Miriam, Marfella, Raffaele, Sasso, Ferdinando Carlo, Coppola, Nicola, and Adinolfi, Luigi Elio

Subjects
vaccination status, COVID-19, predictors of mortality, monoclonal antibodie
Abstract

Background: There is a scarcity of data on outcomes and predictors of therapeutic failure of mAbs in frail COVID-19 patients. Methods: Prospective study including consecutive COVID-19 outpatients referred by primary care physicians for mAbs treatment. Outcomes evaluated were 60-day mortality, time to SARS-CoV-2 clearance, need for hospitalization, and O2-therapy. Results: Among 1026 COVID-19 patients enrolled, 60.2% received casirivamab/imdevimab and 39.8% sotrivimab. Median age was 63 years, 52.4% were males and median time from positive nasopharyngeal swab to mAbs administration was 3 days [IQR, 2-5]. 78.1% were vaccinated. Overall, 60-day mortality was 2.14%. No differences in outcomes were observed between the two mAbs used. No difference was observed in mortality between vaccinated and unvaccinated patients (p=0.925), although lower rate of hospitalization (p

Published
2023

24. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?

Author

Nevola, Riccardo, primary, Delle Femine, Augusto Delle, additional, Rosato, Valerio, additional, Kondili, Loreta Anesti, additional, Alfano, Maria, additional, Mastrocinque, Davide, additional, Imbriani, Simona, additional, Perillo, Pasquale, additional, Beccia, Domenico, additional, Villani, Angela, additional, Ruocco, Rachele, additional, Criscuolo, Livio, additional, La Montagna, Marco La, additional, Russo, Antonio, additional, Marrone, Aldo, additional, Sasso, Ferdinando Carlo, additional, Marfella, Raffaele, additional, Rinaldi, Luca, additional, Esposito, Nicolino, additional, Barberis, Giuseppe, additional, and Claar, Ernesto, additional

Published
2023
Full Text
View/download PDF

25. Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives

Author

Nevola, Riccardo, primary, Villani, Angela, primary, Imbriani, Simona, primary, Alfano, Maria, primary, Criscuolo, Livio, primary, Beccia, Domenico, primary, Ruocco, Rachele, primary, Femine, Augusto Delle, primary, Gragnano, Felice, primary, Cozzolino, Domenico, primary, Marfella, Raffaele, primary, Adinolfi, Luigi Elio, primary, Sasso, Ferdinando Carlo, primary, and Rinaldi, Luca, primary

Published
2023
Full Text
View/download PDF

26. HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis

Author

Nevola, Riccardo, primary, Beccia, Domenico, additional, Rosato, Valerio, additional, Ruocco, Rachele, additional, Mastrocinque, Davide, additional, Villani, Angela, additional, Perillo, Pasquale, additional, Imbriani, Simona, additional, Delle Femine, Augusto, additional, Criscuolo, Livio, additional, Alfano, Maria, additional, La Montagna, Marco, additional, Russo, Antonio, additional, Marfella, Raffaele, additional, Cozzolino, Domenico, additional, Sasso, Ferdinando Carlo, additional, Rinaldi, Luca, additional, Marrone, Aldo, additional, Adinolfi, Luigi Elio, additional, and Claar, Ernesto, additional

Published
2023
Full Text
View/download PDF

27. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study

Author

Rinaldi, Luca, Perrella, Alessandro, Guarino, Maria, De Luca, Massimo, Piai, Guido, Coppola, Nicola, Pafundi, Pia Clara, Ciardiello, Fortunato, Fasano, Morena, Martinelli, Erika, Valente, Giovanna, Nevola, Riccardo, Monari, Caterina, Miglioresi, Lucia, Guerrera, Barbara, Berretta, Massimiliano, Sasso, Ferdinando Carlo, Morisco, Filomena, Izzi, Antonio, and Adinolfi, Luigi Elio

Published
2019
Full Text
View/download PDF

28. Predictors of early and late hepatocellular carcinoma recurrence

Author

Nevola, Riccardo, primary, Ruocco, Rachele, additional, Criscuolo, Livio, additional, Villani, Angela, additional, Alfano, Maria, additional, Beccia, Domenico, additional, Imbriani, Simona, additional, Claar, Ernesto, additional, Cozzolino, Domenico, additional, Sasso, Ferdinando Carlo, additional, Marrone, Aldo, additional, Adinolfi, Luigi Elio, additional, and Rinaldi, Luca, additional

Published
2023
Full Text
View/download PDF

33. Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA Study

Author

Galiero, Raffaele, Simeon, Vittorio, Loffredo, Giuseppe, Caturano, Alfredo, Rinaldi, Luca, Vetrano, Erica, Medicamento, Giulia, Alfano, Maria, Beccia, Domenico, Brin, Chiara, Colantuoni, Sara, Di Salvo, Jessica, Epifani, Raffaella, Nevola, Riccardo, Marfella, Raffaele, Sardu, Celestino, Coppola, Carmine, Scarano, Ferdinando, Maggi, Paolo, Calabrese, Cecilia, De Lucia Sposito, Pellegrino, Rescigno, Carolina, Sbreglia, Costanza, Fraganza, Fiorentino, Parrella, Roberto, Romano, Annamaria, Calabria, Giosuele, Polverino, Benedetto, Pagano, Antonio, Numis, Fabio Giuliano, Bologna, Carolina, Nunziata, Mariagrazia, Esposito, Vincenzo, Coppola, Nicola, Maturo, Nicola, Nasti, Rodolfo, Di Micco, Pierpaolo, Perrella, Alessandro, Lettieri, Miriam, Adinolfi, Luigi Elio, Chiodini, Paolo, Sasso, Ferdinando Carlo, On Behalf Of Covoca Study Group, null, Galiero, Raffaele, Simeon, Vittorio, Loffredo, Giuseppe, Caturano, Alfredo, Rinaldi, Luca, Vetrano, Erica, Medicamento, Giulia, Alfano, Maria, Beccia, Domenico, Brin, Chiara, Colantuoni, Sara, Di Salvo, Jessica, Epifani, Raffaella, Nevola, Riccardo, Marfella, Raffaele, Sardu, Celestino, Coppola, Carmine, Scarano, Ferdinando, Maggi, Paolo, Calabrese, Cecilia, De Lucia Sposito, Pellegrino, Rescigno, Carolina, Sbreglia, Costanza, Fraganza, Fiorentino, Parrella, Roberto, Romano, Annamaria, Calabria, Giosuele, Polverino, Benedetto, Pagano, Antonio, Numis, Fabio Giuliano, Bologna, Carolina, Nunziata, Mariagrazia, Esposito, Vincenzo, Coppola, Nicola, Maturo, Nicola, Nasti, Rodolfo, Di Micco, Pierpaolo, Perrella, Alessandro, Lettieri, Miriam, Adinolfi, Luigi Elio, Chiodini, Paolo, Sasso, Ferdinando Carlo, and On Behalf Of Covoca Study Group, Null

Subjects
COVID-19, chronic kidney diseases, in-hospital mortality, General Medicine, chronic kidney disease
Abstract

Background. Evidence has shown a close association between COVID-19 infection and renal complications in both individuals with previously normal renal function and those with chronic kidney disease (CKD). Methods. The aim of this study is to evaluate the in-hospital mortality of SARS-CoV-2 patients according to their clinical history of CKD or estimated glomerular filtration rate (eGFR). This is a prospective multicenter observational cohort study which involved adult patients (≥18 years old) who tested positive with SARS-CoV-2 infection and completed their hospitalization in the period between November 2020 and June 2021. Results. 1246 patients were included in the study, with a mean age of 64 years (SD 14.6) and a median duration of hospitalization of 15 days (IQR 9–22 days). Cox’s multivariable regression model revealed that mortality risk was strongly associated with the stage of renal impairment and the Kaplan–Meier survival analysis showed a progressive and statistically significant difference (p < 0.0001) in mortality according to the stage of CKD. Conclusion. This study further validates the association between CKD stage at admission and mortality in patients hospitalized for COVID-19. The risk stratification based on eGFR allows clinicians to identify the subjects with the highest risk of intra-hospital mortality despite the duration of hospitalization.

Published
2022

34. Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study

Author

Marrone, Aldo, Nevola, Riccardo, Sellitto, Ausilia, Cozzolino, Domenico, Romano, Ciro, Cuomo, Giovanna, Aprea, Concetta, Schwartzbaum, Michelangelo X Palou, Ricozzi, Carmen, Imbriani, Simona, Rinaldi, Luca, Gjeloshi, Klodian, Padula, Andrea, Ranieri, Roberta, Ruosi, Carolina, Meo, Luciana Agnese, Abitabile, Marianna, Cinone, Francesca, Carusone, Caterina, Adinolfi, Luigi Elio, Marrone, Aldo, Nevola, Riccardo, Sellitto, Ausilia, Cozzolino, Domenico, Romano, Ciro, Cuomo, Giovanna, Aprea, Concetta, Schwartzbaum, Michelangelo X Palou, Ricozzi, Carmen, Imbriani, Simona, Rinaldi, Luca, Gjeloshi, Klodian, Padula, Andrea, Ranieri, Roberta, Ruosi, Carolina, Meo, Luciana Agnese, Abitabile, Marianna, Cinone, Francesca, Carusone, Caterina, and Adinolfi, Luigi Elio

Subjects
Dexamethasone. Survival, Remdesivir, COVID-19, viral clearance
Abstract

Background: Remdesivir is an antiviral used to treat COVID-19 which improves some clinical outcomes. Dexamethasone has been shown to be effective in reducing mortality. It has been hypothesized that combination of these two drugs can improve mortality. We evaluated the effect of combination on mortality of COVID-19 patients requiring O2 therapy. Methods: A prospective quasi-experimental study, including two independent, sequential controlled cohorts, one received remdesivir-dexamethasone and the other dexamethasone alone, was designed. All COVID-19 patients requiring supplemental O2 therapy were enrolled consecutively. The sample size to power mortality was a priori calculated. The primary endpoints were 30-day mortality and viral clearance differences. Secondary endpoints were differences in hospitalization times, improvement in respiratory failure (PO2/FiO2) and inflammatory indices (fibrinogen, CRP, neutrophil/lymphocyte ratio, D-Dimer). Kaplan-Meier curves and the log-rank test were used to evaluate significant differences in mortality between groups. Results: 151 COVID-19 patients were enrolled (remdesivir/dexamethasone group, 76 and dexamethasone alone,75). No differences in demographic, clinical and laboratory characteristics were observed between the two groups at baseline. Faster viral clearance occurred in the remdesivir/dexamethasone group compared to dexamethasone alone (median 6 vs 16 days; p

Published
2022

37. Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies

Author

Nevola, Riccardo, primary, Rosato, Valerio, additional, Conturso, Vincenza, additional, Perillo, Pasquale, additional, Le Pera, Teresa, additional, Del Vecchio, Ferdinando, additional, Mastrocinque, Davide, additional, Pappalardo, Annalisa, additional, Imbriani, Simona, additional, Delle Femine, Augusto, additional, Piacevole, Alessia, additional, and Claar, Ernesto, additional

Published
2022
Full Text
View/download PDF

38. Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic

Author

Rosato, Valerio, primary, Nevola, Riccardo, additional, Conturso, Vincenza, additional, Perillo, Pasquale, additional, Mastrocinque, Davide, additional, Pappalardo, Annalisa, additional, Le Pera, Teresa, additional, Del Vecchio, Ferdinando, additional, and Claar, Ernesto, additional

Published
2022
Full Text
View/download PDF

40. Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early Recognition of Inflamed Thoracic Areas Spreading)

Author

Romano, Ciro, primary, Cozzolino, Domenico, additional, Cuomo, Giovanna, additional, Abitabile, Marianna, additional, Carusone, Caterina, additional, Cinone, Francesca, additional, Nappo, Francesco, additional, Nevola, Riccardo, additional, Sellitto, Ausilia, additional, Auricchio, Annamaria, additional, Cardella, Francesca, additional, Del Sorbo, Giovanni, additional, Lieto, Eva, additional, Galizia, Gennaro, additional, Adinolfi, Luigi Elio, additional, Marrone, Aldo, additional, and Rinaldi, Luca, additional

Published
2022
Full Text
View/download PDF

41. Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology?

Author

Nevola, Riccardo, primary, Messina, Vincenzo, additional, Marrone, Aldo, additional, Coppola, Nicola, additional, Rescigno, Carolina, additional, Esposito, Vincenzo, additional, Sangiovanni, Vincenzo, additional, Claar, Ernesto, additional, Pisaturo, Mariantonietta, additional, Fusco, Francesco Maria, additional, Rosario, Pietro, additional, Izzi, Antonio, additional, Pisapia, Raffaella, additional, Rosato, Valerio, additional, Maggi, Paolo, additional, and Adinolfi, Luigi Elio, additional

Published
2022
Full Text
View/download PDF

43. Additional file 1 of The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial

Author

Sasso, Ferdinando Carlo, Simeon, Vittorio, Galiero, Raffaele, Caturano, Alfredo, De Nicola, Luca, Chiodini, Paolo, Rinaldi, Luca, Salvatore, Teresa, Lettieri, Miriam, Nevola, Riccardo, Sardu, Celestino, Docimo, Giovanni, Loffredo, Giuseppe, Marfella, Raffaele, Adinolfi, Luigi Elio, and Minutolo, Roberto

Abstract

Additional file 1: Table S1. Test of Likelihood ratio for interaction term. Table S2. Test of proportional-hazards assumption. Table S3. Sensitivity analysis comparing patients with absent information for at least one of the variables included in the score (missing group) and those without missing data. Table S4. Risks for MACEs and all-cause mortality by risk group at univariate Cox model and after adjustment for confounding variables. Figure S1. Sensitivity analysis comparing survival estimates for MACE and overall survival (OS) in patients with absent information for at least one of the variables included in the score (missing group) and those without missing data.

Published
2022
Full Text
View/download PDF

44. Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study

Author

Marrone, Aldo, primary, Nevola, Riccardo, additional, Sellitto, Ausilia, additional, Cozzolino, Domenico, additional, Romano, Ciro, additional, Cuomo, Giovanna, additional, Aprea, Concetta, additional, Schwartzbaum, Michelangelo X Palou, additional, Ricozzi, Carmen, additional, Imbriani, Simona, additional, Rinaldi, Luca, additional, Gjeloshi, Klodian, additional, Padula, Andrea, additional, Ranieri, Roberta, additional, Ruosi, Carolina, additional, Meo, Luciana Agnese, additional, Abitabile, Marianna, additional, Cinone, Francesca, additional, Carusone, Caterina, additional, and Adinolfi, Luigi Elio, additional

Published
2022
Full Text
View/download PDF

45. Efficacy and durability of multifactorial intervention on mortality and MACEs:a randomized clinical trial in type-2 diabetic kidney disease

Author

Sasso, F. C., Pafundi, Pia Clara, Simeon, Vittorio, De Nicola, L., Chiodini, Paolo, Galiero, Raffaele, Rinaldi, Luca, Nevola, Riccardo, Salvatore, Teresa, Sardu, Celestino, Marfella, Raffaele, Adinolfi, Luigi Elio, Minutolo, R., Amelia, U., Acierno, C., Calatola, P., Carbonara, O., Caturano, A., Conte, G., Corigliano, G., Corigliano, M., D’Urso, R., De Matteo, A., De Rosa, N., Del Vecchio, E., Di Giovanni, G., Gatti, A., Gentile, S., Gesuè, L., Improta, L., Lampitella, A., Lanzilli, A., Lascar, N., Masi, S., Mattei, P., Mastrilli, V., Memoli, P., Nasti, R., Pagano, A., Pentangelo, M., Pisa, E., Rossi, E., Sorrentino, S., Torella, R., Troise, R., Trucillo, P., and NID-2 Study Group Investigators

Abstract

Background: Multiple modifiable risk factors for late complications in patients with diabetic kidney disease (DKD), including hyperglycemia, hypertension and dyslipidemia, increase the risk of a poor outcome. DKD is associated with a very high cardiovascular risk, which requires simultaneous treatment of these risk factors by implementing an intensified multifactorial treatment approach. However, the efficacy of a multifactorial intervention on major fatal/non-fatal cardiovascular events (MACEs) in DKD patients has been poorly investigated. Methods: Nephropathy in Diabetes type 2 (NID-2) study is a multicentre, cluster-randomized, open-label clinical trial enrolling 395 DKD patients with albuminuria, diabetic retinopathy (DR) and negative history of CV events in 14 Italian diabetology clinics. Centres were randomly assigned to either Standard-of-Care (SoC) (n = 188) or multifactorial intensive therapy (MT, n = 207) of main cardiovascular risk factors (blood pressure < 130/80 mmHg, glycated haemoglobin < 7%, LDL, HDL and total cholesterol < 100 mg/dL, > 40/50 mg/dL for men/women and < 175 mg/dL, respectively). Primary endpoint was MACEs occurrence by end of follow-up phase. Secondary endpoints included single components of primary endpoint and all-cause death. Results: At the end of intervention period (median 3.84 and 3.40 years in MT and SoC group, respectively), targets achievement was significantly higher in MT. During 13.0 years (IQR 12.4–13.3) of follow-up, 262 MACEs were recorded (116 in MT vs. 146 in SoC). The adjusted Cox shared-frailty model demonstrated 53% lower risk of MACEs in MT arm (adjusted HR 0.47, 95%CI 0.30–0.74, P = 0.001). Similarly, all-cause death risk was 47% lower (adjusted HR 0.53, 95%CI 0.29–0.93, P = 0.027). Conclusion: MT induces a remarkable benefit on the risk of MACEs and mortality in high-risk DKD patients. Clinical Trial Registration ClinicalTrials.gov number, NCT00535925. https://clinicaltrials.gov/ct2/show/NCT00535925

Published
2021

47. Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study

Author

Rosato, Valerio, primary, Ascione, Antonio, additional, Nevola, Riccardo, additional, Fracanzani, Anna Ludovica, additional, Piai, Guido, additional, Messina, Vincenzo, additional, Claar, Ernesto, additional, Coppola, Carmine, additional, Fontanella, Luca, additional, Lombardi, Rosa, additional, Staiano, Laura, additional, Valente, Giovanna, additional, Fascione, Maria Chiara, additional, Giorgione, Chiara, additional, Mazzocca, Annalisa, additional, Galiero, Raffaele, additional, Perillo, Pasquale, additional, Marrone, Aldo, additional, Sasso, Ferdinando Carlo, additional, Adinolfi, Luigi Elio, additional, and Rinaldi, Luca, additional

Published
2021
Full Text
View/download PDF

48. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

Author

Sasso, Ferdinando Carlo, primary, Pafundi, Pia Clara, additional, Caturano, Alfredo, additional, Galiero, Raffaele, additional, Vetrano, Erica, additional, Nevola, Riccardo, additional, Petta, Salvatore, additional, Fracanzani, Anna Ludovica, additional, Coppola, Carmine, additional, Di Marco, Vito, additional, Solano, Antonio, additional, Lombardi, Rosa, additional, Giordano, Mauro, additional, Craxi, Antonio, additional, Perrella, Alessandro, additional, Sardu, Celestino, additional, Marfella, Raffaele, additional, Salvatore, Teresa, additional, Adinolfi, Luigi Elio, additional, and Rinaldi, Luca, additional

Published
2021
Full Text
View/download PDF

49. Additional file 1 of Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease

Author

Sasso, Ferdinando Carlo, Pafundi, Pia Clara, Simeon, Vittorio, De Nicola, Luca, Chiodini, Paolo, Galiero, Raffaele, Rinaldi, Luca, Nevola, Riccardo, Salvatore, Teresa, Sardu, Celestino, Marfella, Raffaele, Adinolfi, Luigi Elio, and Minutolo, Roberto

Abstract

Additional file 1: Appendix S1. Intervention by randomization.

Published
2021
Full Text
View/download PDF

50. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study

Author

Adinolfi, Luigi Elio, Petta, Salvatore, Fracanzani, Anna Ludovica, Coppola, Carmine, Narciso, Vincenzo, Nevola, Riccardo, Rinaldi, Luca, Calvaruso, Vincenza, Staiano, Laura, Di Marco, Vito, Marrone, Aldo, Pafundi, Pia Clara, Solano, Antonio, Lombardi, Rosa, Sasso, Ferdinando Carlo, Saturnino, Mariarosaria, Rini, Francesca, Guerrera, Barbara, Troina, Graziano, Giordano, Mauro, and Craxì, Antonio

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results